SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...

Aardvark Therapeutics, Inc. ("Aardvark") (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...

Truist Securities maintained their Hold rating on Shopify shares (NYSE:SHOP), with a steady price target of $120.00, close to the current trading price of $119.43. Following the release of the company ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES LONDON, UK / ACCESS Newswire / February 13, 2025 / Gabriel Resources Ltd. ("Gabriel" or the "Company" ...

Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...

Cantor Fitzgerald upgraded CVS Health (NYSE:CVS) to Overweight from Neutral and increased its 12-month per-share target to $71 from $62 on Wednesday after the managed care giant delivered better ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Cantor Fitzgerald has a “Neutral” rating and a $110.00 price objective on the stock. The consensus estimate for Fortinet’s current full-year earnings is $2.05 per share. Get Fortinet alerts: ...

Cantor Fitzgerald currently has a $170.00 price objective on the biotechnology company’s stock. Other analysts also recently issued research reports about the stock. StockNews.com upgraded ...

Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating ... though InvestingPro's Fair Value analysis suggests the stock is currently trading at a premium to its intrinsic value.

The Overweight rating by Cantor Fitzgerald indicates the firm's positive outlook on ORIC Pharmaceuticals' stock, suggesting that the analysts believe the stock could outperform the average total ...